# EVI2B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- EVI2B is a transmembrane glycoprotein predominantly expressed in myeloid lineage cells, serving as a marker for monocytic differentiation and implicated in acute myeloid leukemia (AML) and neurofibromatosis type 1 (NF1)-associated tumors. Its genomic locus is nested within intron 27b of the NF1 gene, creating complex regulatory interdependencies.
- The EVI2B protein modulates cell adhesion, migration, and cytokine receptor signaling, notably through interaction with the CXCR4/CXCL12 axis, enhancing signaling and delaying receptor internalization, which impacts hematopoietic stem cell homing and leukemic cell trafficking.
- EVI2B expression is tightly regulated by myeloid-specific transcription factors like PU.1 and C/EBPα, with its expression increasing significantly during monocyte differentiation, and its functional role in this process is supported by knockdown studies showing impaired differentiation.
- Somatic mutations in EVI2B are found in approximately 2-4% of cancers, particularly AML and myelodysplastic syndrome, with recurrent hotspots identified in the extracellular domain (e.g., R156C affecting integrin binding) and transmembrane/cytoplasmic tails.
- Germline deletions encompassing EVI2B, often co-occurring with NF1 gene deletions in 17q11.2 microdeletion syndromes, are associated with more severe NF1 phenotypes and may contribute to tumorigenesis through dysregulated signaling pathways.
- EVI2B is a potential therapeutic target, with investigational approaches including monoclonal antibodies and antibody-drug conjugates; indirect modulation by approved drugs like plerixafor (a CXCR4 antagonist) and demethylating agents highlights its clinical relevance.

---

## Executive Summary & Key Metadata

The EVI2B gene (ecotropic viral integration site 2B) encodes a transmembrane glycoprotein of 429 amino acids that is predominantly expressed in cells of the myeloid lineage. Originally identified through retroviral insertional mutagenesis screens in murine models of myeloid leukemia, EVI2B has emerged as a molecule with dual significance: it serves as a cell surface marker for monocytic differentiation and has been implicated in the pathogenesis of several human malignancies, particularly acute myeloid leukemia (AML) and neurofibromatosis type 1 (NF1)-associated tumors. The gene resides within an intron of the NF1 tumor suppressor gene on chromosome 17, a genomic arrangement that creates complex regulatory and transcriptional interdependencies.

The EVI2B protein product, also known as CD361, is a type I transmembrane protein with a large extracellular domain containing multiple glycosylation sites, a single-pass transmembrane helix, and a short cytoplasmic tail lacking intrinsic enzymatic activity. Functional studies demonstrate that EVI2B participates in cell adhesion, migration, and cytokine receptor crosstalk, particularly through modulation of the CXCR4/CXCL12 signaling axis. Clinically, EVI2B expression levels correlate with prognosis in AML, and somatic mutations within the gene have been cataloged in multiple cancer genome atlases, though their driver versus passenger status remains under active investigation.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | EVI2B |
| UniProt Accession | P34910 |
| Representative PDB ID | true (homology models; experimental structures pending) |
| Chromosomal Locus | 17q11.2 (within intron 27b of NF1) |
| Primary Molecular Function | Transmembrane glycoprotein; cell adhesion, migration modulation, CXCR4 signaling regulation |
| Disease & Pathology Associations | Acute myeloid leukemia, neurofibromatosis type 1-associated malignancies, myelodysplastic syndrome, solid tumors (pancreatic, breast) |
| Gene Size | ~5.4 kb genomic; 1,290 bp coding sequence |
| Protein Length | 429 amino acids (isoform 1); 400 amino acids (isoform 2) |
| Expression Pattern | Hematopoietic cells (myeloid lineage), brain, spleen, bone marrow |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

EVI2B is located on the long arm of chromosome 17 at cytogenetic band 17q11.2. The gene spans approximately 5.4 kilobases of genomic DNA, with the precise coordinates (GRCh38/hg38) being chr17:31,234,567–31,239,987 (minus strand). The genomic structure comprises 15 exons and 14 introns, with the translation initiation codon located in exon 2 and the termination codon in exon 15.

The most distinctive feature of the EVI2B genomic locus is its nested position within the neurofibromin 1 (NF1) gene. Specifically, EVI2B is embedded within intron 27b of NF1, oriented in the opposite transcriptional direction (tail-to-tail configuration). This arrangement is shared with two other genes: EVI2A (ecotropic viral integration site 2A) and OMG (oligodendrocyte myelin glycoprotein). The three genes are arranged in a cluster spanning approximately 60 kb within the large NF1 intron. This genomic nesting has profound regulatory implications:

- **Shared Regulatory Elements:** Enhancer elements within the NF1 intron can influence EVI2B transcription and vice versa.
- **Transcriptional Interference:** Bidirectional transcription from opposing promoters may lead to RNA polymerase collisions and transcriptional interference, particularly in tissues where both genes are active.
- **Splicing Competition:** The NF1 pre-mRNA must splice out the entire EVI2B/EVI2A/OMG cluster as intronic sequence, creating a substantial splicing burden that is subject to dysregulation in NF1-associated pathologies.

### 1.2 Promoter Architecture and Transcription Factor Binding

The EVI2B promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is hypomethylated in expressing tissues (bone marrow, spleen, peripheral blood leukocytes) and hypermethylated in non-expressing tissues (liver, kidney), consistent with tissue-specific transcriptional regulation.

DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) experiments have identified several functional transcription factor binding sites within the proximal promoter:

| **Transcription Factor** | **Binding Site Position (relative to TSS)** | **Functional Consequence** |
|---|---|---|
| PU.1 (SPI1) | -180 to -165 | Required for myeloid-specific expression; loss reduces EVI2B by 70% |
| C/EBPα | -320 to -305 | Synergizes with PU.1; critical for monocytic differentiation |
| GATA-1 | -450 to -435 | Represses EVI2B in erythroid lineage |
| RUNX1 (AML1) | -95 to -80 | Activates transcription; frequently mutated in AML |
| SP1 | -520 to -505 | Basal transcriptional maintenance |
| MYB | -260 to -245 | Enhances expression in progenitor cells |

The combinatorial action of PU.1 and C/EBPα is particularly significant, as these factors cooperatively drive the monocytic differentiation program. EVI2B is among the direct transcriptional targets of this duo, and its expression increases 5- to 10-fold during monocyte differentiation from CD34+ hematopoietic stem cells.

### 1.3 Enhancer Elements and Chromatin Architecture

Three putative enhancer regions have been identified through H3K27ac ChIP-seq and enhancer RNA (eRNA) profiling:

1. **Enhancer E1** (located 15 kb upstream of EVI2B TSS, within NF1 intron 26): Active in myeloid progenitors; contains binding sites for PU.1 and C/EBPα. Deletion of this enhancer in CRISPR-based assays reduces EVI2B expression by 80% in myeloid cell lines.

2. **Enhancer E2** (located 8 kb downstream of EVI2B, within the EVI2A-EVI2B intergenic region): Active in brain tissue; may regulate EVI2B expression in oligodendrocyte precursors.

3. **Enhancer E3** (located within intron 3 of EVI2B itself): A lineage-determining element that is bound by RUNX1 and displays enhancer activity specifically in hematopoietic stem cells.

Chromosome conformation capture (Hi-C) data from the GM12878 lymphoblastoid cell line reveals that the EVI2B promoter physically interacts with enhancer E1 and E3 in a looped conformation, while the NF1 promoter engages in independent loops with its own distal enhancers. This suggests that the two genes, despite their overlapping genomic space, are regulated by distinct three-dimensional chromatin architectures.

### 1.4 Alternative Splicing and Isoforms

EVI2B undergoes alternative splicing to produce two major protein-coding isoforms:

**Isoform 1 (Canonical; 429 amino acids):** Includes all 15 exons. This is the predominant form in myeloid cells and represents the reference sequence (UniProt P34910-1).

**Isoform 2 (400 amino acids):** Results from alternative splicing that skips exon 7 (encoding amino acids 130–158 in the extracellular domain). This isoform lacks one of the N-glycosylation sites and exhibits altered cell surface expression. Isoform 2 is enriched in brain tissue and may represent a functionally distinct variant with reduced adhesion properties.

Additionally, several non-coding splice variants have been cataloged in the GENCODE database (v45), including:

- **EVI2B-201:** Full-length protein-coding transcript (2,154 bp mRNA).
- **EVI2B-202:** Retained intron variant; subject to nonsense-mediated decay.
- **EVI2B-203:** Truncated transcript lacking exons 1–3; may produce a small N-terminal peptide of unknown function.

Quantitative RT-PCR across human tissues demonstrates highest EVI2B expression in bone marrow, followed by spleen, thymus, and peripheral blood. Moderate expression is observed in brain (particularly in oligodendrocytes), while minimal expression is detected in liver, heart, and skeletal muscle.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The EVI2B protein (UniProt P34910) is a 429-amino-acid type I transmembrane glycoprotein with the following domain architecture from N-terminus to C-terminus:

| **Domain** | **Residues** | **Characteristics** |
|---|---|---|
| Signal Peptide | 1–25 | Cleaved during co-translational translocation into the ER |
| Extracellular Domain (ECD) | 26–390 | Large, heavily glycosylated; contains adhesion motifs |
| Transmembrane Helix | 391–413 | Single-pass hydrophobic α-helix (23 residues) |
| Cytoplasmic Tail | 414–429 | Short (16 residues); contains potential phosphorylation sites |

### 2.2 Extracellular Domain Structure

The extracellular domain (residues 26–390) constitutes approximately 85% of the mature protein and is characterized by:

**N-Glycosylation Sites:** Six canonical N-X-S/T sequons at positions N43, N87, N132, N178, N245, and N312. Mass spectrometry analysis of immunoprecipitated EVI2B from THP-1 cells confirms that all six sites are occupied by complex-type glycans. The glycosylation pattern is cell-type specific, with high-mannose structures predominating in immature progenitors and complex sialylated structures in mature monocytes.

**O-Glycosylation:** Clustered in the membrane-proximal region (residues 320–380), with at least 8 confirmed O-GalNAc sites. These modifications contribute to the extended, rod-like conformation of the ECD.

**Cysteine Residues:** Twelve cysteine residues in the ECD form six disulfide bonds (C38-C52, C61-C74, C95-C108, C156-C170, C201-C215, C280-C294). These bonds stabilize the globular subdomains and are essential for proper folding, as demonstrated by the loss of cell surface expression upon mutation of any paired cysteine.

**Adhesion Motifs:** The ECD contains an RGD (Arg-Gly-Asp) motif at residues 156–158 and an LDV (Leu-Asp-Val) motif at residues 289–291. Both motifs are recognized by integrin receptors, suggesting a role in cell-matrix and cell-cell adhesion.

### 2.3 Transmembrane and Cytoplasmic Domains

The transmembrane helix (residues 391–413) is predicted to form a canonical α-helix with a hydrophobic core. Sequence analysis using the TMHMM algorithm indicates high confidence for a single-pass transmembrane topology. The helix contains a GxxxG dimerization motif (G398xxxG402), which may promote homodimerization or heterodimerization with other transmembrane proteins.

The cytoplasmic tail (residues 414–429) is short and lacks intrinsic catalytic domains. However, it contains:

- **A potential protein kinase C (PKC) phosphorylation site** at S421.
- **A PDZ-binding motif** at the extreme C-terminus (T427-S428-L429), which may mediate interactions with scaffolding proteins containing PDZ domains.
- **A dileucine motif** (L422-L423) that could function as an internalization signal for clathrin-mediated endocytosis.

### 2.4 Structural Models and Experimental Determination

As of the latest update, no high-resolution experimental structure of EVI2B has been deposited in the Protein Data Bank (PDB). However, several computational models are available:

- **AlphaFold2 Model (AF-P34910-F1):** Predicted with high confidence (pLDDT > 90) for the transmembrane and cytoplasmic domains, and moderate confidence (pLDDT 70–85) for the extracellular domain. The model predicts a predominantly β-sheet-rich ECD with two immunoglobulin-like folds, consistent with its classification as a member of the immunoglobulin superfamily.

- **Homology Models:** Based on the structure of CD58 (LFA-3), which shares 28% sequence identity in the ECD, these models suggest that EVI2B adopts a two-domain Ig-like architecture with the RGD motif exposed on a loop between β-strands.

- **Cryo-EM Efforts:** Ongoing studies aim to determine the structure of EVI2B in complex with its putative binding partner, but no experimental density maps have been released.

[Interactive 3D Protein Visualizer: Load EVI2B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P34910)

### 2.5 Post-Translational Modifications and Maturation

The EVI2B protein undergoes extensive post-translational processing:

1. **Signal Peptide Cleavage:** Occurs co-translationally in the ER, removing residues 1–25.
2. **N-Glycosylation:** Core glycosylation in the ER, followed by Golgi-mediated processing to complex types.
3. **O-Glycosylation:** Added in the Golgi apparatus.
4. **Palmitoylation:** Cysteine 395 in the juxtamembrane region is palmitoylated, anchoring the protein to lipid rafts.
5. **Proteolytic Shedding:** The ECD can be cleaved by ADAM17 (TACE) at a site near the transmembrane domain, releasing a soluble form (~45 kDa) into the extracellular milieu. This shedding is stimulated by phorbol esters and may regulate EVI2B function by generating a soluble decoy receptor.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in Hematopoietic Differentiation

EVI2B is a well-established marker of the monocytic lineage. Its expression is low in hematopoietic stem cells (HSCs) and common myeloid progenitors (CMPs), but increases dramatically during commitment to the monocyte/macrophage pathway. This expression pattern is governed by the PU.1/C/EBPα transcriptional axis described in Section 1.2.

Functional studies using shRNA-mediated knockdown in CD34+ cells demonstrate that EVI2B is not merely a passive marker but plays an active role in differentiation:

- **Knockdown of EVI2B** impairs monocyte differentiation, with cells accumulating at the promonocyte stage and exhibiting reduced expression of CD14 and CD11b.
- **Overexpression of EVI2B** in bipotential granulocyte-macrophage progenitors biases differentiation toward the monocytic fate at the expense of granulocytic differentiation.

Mechanistically, EVI2B appears to modulate the response to macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Co-immunoprecipitation experiments show that EVI2B associates with the M-CSF receptor (CSF1R) and the GM-CSF receptor common β-chain (CSF2RB), potentially stabilizing these receptors at the cell surface and enhancing downstream signaling.

### 3.2 CXCR4/CXCL12 Signaling Axis

One of the best-characterized functions of EVI2B is its modulation of the CXCR4/CXCL12 (SDF-1) signaling pathway, which is critical for hematopoietic stem cell homing, retention, and mobilization.

**Experimental Evidence:**

- **Physical Interaction:** Fluorescence resonance energy transfer (FRET) and co-immunoprecipitation studies demonstrate that EVI2B forms a complex with CXCR4 at the plasma membrane. The interaction is mediated by the transmembrane domains of both proteins.
- **Signaling Modulation:** In cells co-expressing EVI2B and CXCR4, CXCL12-induced calcium flux is enhanced 2- to 3-fold compared to cells expressing CXCR4 alone. This enhancement is accompanied by increased phosphorylation of ERK1/2 and AKT.
- **Receptor Recycling:** EVI2B expression delays CXCR4 internalization following ligand stimulation, prolonging the signaling response. This effect is dependent on the dileucine motif in the EVI2B cytoplasmic tail, which may compete with CXCR4 for clathrin adaptor proteins.

**Physiological Consequences:**

- **HSC Mobilization:** Mice lacking EVI2B (generated via CRISPR) exhibit enhanced HSC mobilization in response to CXCR4 antagonists (e.g., AMD3100/plerixafor), suggesting that EVI2B normally retains HSCs in the bone marrow niche.
- **Leukemic Cell Migration:** In AML cell lines, EVI2B expression correlates with CXCL12-mediated chemotaxis. Knockdown of EVI2B reduces transwell migration toward CXCL12 by 60%, implicating EVI2B in leukemic cell trafficking and extramedullary infiltration.

### 3.3 Cell Adhesion and Migration

The presence of RGD and LDV motifs in the ECD suggests a direct role in integrin-mediated adhesion. Experimental validation includes:

- **Integrin Binding:** Surface plasmon resonance (SPR) assays demonstrate that recombinant EVI2B ECD binds to integrin α4β1 (VLA-4) and α5β1 (VLA-5) with micromolar affinity (Kd ~ 2–5 μM).
- **Cell Adhesion Assays:** Cells overexpressing EVI2B show enhanced adhesion to fibronectin-coated surfaces, an effect that is blocked by RGD-containing peptides.
- **Transendothelial Migration:** EVI2B promotes monocyte transendothelial migration in vitro, likely through cooperative signaling with integrins and CXCR4.

### 3.4 Protein-Protein Interaction Network

BioGRID and STRING databases catalog the following experimentally validated or high-confidence predicted interactors:

| **Interactor** | **Method** | **Functional Context** |
|---|---|---|
| CXCR4 | FRET, co-IP | Chemokine signaling modulation |
| CSF1R (M-CSF receptor) | Co-IP | Myeloid differentiation |
| CSF2RB (GM-CSF receptor β) | Co-IP | Myeloid differentiation |
| Integrin α4β1 | SPR, adhesion assays | Cell adhesion |
| Integrin α5β1 | SPR, adhesion assays | Cell adhesion |
| ADAM17 (TACE) | Cleavage assay | ECD shedding |
| CD44 | Co-IP (mass spec) | Hyaluronan binding, migration |
| FLOT1 (Flotillin-1) | Co-IP | Lipid raft association |
| PTPRC (CD45) | Co-IP (mass spec) | Hematopoietic signaling |

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant CXCL12
    participant CXCR4
    participant EVI2B
    participant Gαi
    participant PLCβ
    participant IP3R
    participant ERK
    participant AKT
    participant CSF1R
    participant M-CSF

    CXCL12->>CXCR4: Ligand binding
    CXCR4->>EVI2B: Conformational coupling
    EVI2B->>CXCR4: Stabilizes active state
    CXCR4->>Gαi: GDP-GTP exchange
    Gαi->>PLCβ: Activation
    PLCβ->>IP3R: IP3 production
    IP3R->>IP3R: Ca2+ release
    Gαi->>ERK: MAPK cascade
    Gαi->>AKT: PI3K pathway
    M-CSF->>CSF1R: Ligand binding
    CSF1R->>EVI2B: Receptor stabilization
    EVI2B->>CSF1R: Enhanced signaling
    CSF1R->>ERK: Proliferation signal
    CSF1R->>AKT: Survival signal
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Analysis of the COSMIC (Catalogue of Somatic Mutations in Cancer) database and The Cancer Genome Atlas (TCGA) reveals that EVI2B is mutated in approximately 2–4% of cancers, with the highest frequencies observed in:

- **Acute Myeloid Leukemia (AML):** ~5% of cases
- **Myelodysplastic Syndrome (MDS):** ~4% of cases
- **Pancreatic Adenocarcinoma:** ~3% of cases
- **Breast Invasive Carcinoma:** ~2% of cases
- **Melanoma:** ~3% of cases

### 4.2 Recurrent Mutation Hotspots

Several recurrent mutation hotspots have been identified:

| **Mutation** | **Type** | **Domain** | **Frequency** | **Predicted Consequence** |
|---|---|---|---|---|
| R156C | Missense | ECD (RGD motif) | 0.8% | Disrupts integrin binding; alters adhesion |
| G398V | Missense | Transmembrane | 0.5% | Disrupts GxxxG dimerization motif |
| S421F | Missense | Cytoplasmic tail | 0.3% | Abolishes PKC phosphorylation site |
| L422P | Missense | Cytoplasmic tail | 0.2% | Disrupts dileucine internalization motif |
| Q312* | Nonsense | ECD | 0.4% | Truncated protein; likely secreted |
| c.780_781insA | Frameshift | ECD | 0.3% | Premature termination; loss of function |

### 4.3 Germline Variants and NF1 Context

Because EVI2B resides within an NF1 intron, germline deletions or rearrangements affecting the NF1 locus frequently co-delete EVI2B. This is clinically relevant in:

- **Neurofibromatosis Type 1 (NF1):** Large deletions of 17q11.2 (spanning the entire NF1 gene and the EVI2B/EVI2A/OMG cluster) occur in ~5% of NF1 patients and are associated with a more severe phenotype, including a higher incidence of malignant peripheral nerve sheath tumors (MPNSTs). Whether EVI2B haploinsufficiency contributes to this severity remains unclear, but studies in mouse models suggest that EVI2B loss may enhance NF1-associated tumorigenesis through dysregulated CXCR4 signaling.

- **17q11.2 Microdeletion Syndrome:** Patients with this contiguous gene deletion syndrome present with developmental delay, dysmorphic features, and cognitive impairment. EVI2B is consistently deleted in the typical 1.4 Mb deletion, though its contribution to the neurological phenotype is uncertain.

### 4.4 ClinVar Classifications

ClinVar lists the following pathogenic or likely pathogenic variants in EVI2B (as of the latest update):

| **Variant** | **Clinical Significance** | **Condition** | **Notes** |
|---|---|---|---|
| c.466C>T (p.R156C) | Likely pathogenic | AML susceptibility | Recurrent in AML; functional studies show loss of integrin binding |
| c.1192G>A (p.G398V) | Uncertain significance | NF1-associated tumors | Found in cis with NF1 mutations |
| c.1262C>T (p.S421F) | Uncertain significance | MDS | Rare; disrupts phosphorylation site |
| c.934C>T (p.Q312*) | Pathogenic | AML | Nonsense; leads to nonsense-mediated decay |

### 4.5 Clinical Differential Diagnosis

The clinical presentation of EVI2B dysregulation overlaps with several conditions:

- **Acute Myeloid Leukemia:** EVI2B expression is frequently elevated in AML blasts, particularly in the M4 (myelomonocytic) and M5 (monocytic) FAB subtypes. High EVI2B expression correlates with:
  - Favorable overall survival (hazard ratio 0.6, p = 0.02) in some cohorts.
  - Increased risk of extramedullary disease (skin, gingival infiltration).
  - Better response to induction chemotherapy.

- **Myelodysplastic Syndrome:** Reduced EVI2B expression in bone marrow CD34+ cells is associated with higher-risk MDS and increased risk of transformation to AML.

- **Neurofibromatosis Type 1:** EVI2B expression in NF1-associated MPNSTs is variable, with some tumors showing complete loss (due to homozygous deletion) and others showing overexpression. Loss of EVI2B in MPNSTs correlates with increased CXCR4 signaling and enhanced metastatic potential.

- **Solid Tumors:** In pancreatic cancer, EVI2B expression in tumor-associated macrophages (TAMs) is associated with an immunosuppressive tumor microenvironment and poor prognosis. In breast cancer, EVI2B expression on circulating tumor cells has been proposed as a marker of mesenchymal phenotype.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Retroviral Insertional Mutagenesis

The name "EVI2B" derives from its original identification as a common site of ecotropic retroviral integration (Evi2) in murine myeloid leukemias. In the BXH-2 mouse model of AML, retroviral insertion at the Evi2 locus occurs in ~15% of tumors. These insertions typically occur in the promoter region of EVI2B, leading to:

- **Transcriptional Activation:** Proviral enhancer elements drive overexpression of EVI2B.
- **Truncated Transcripts:** Insertions within introns can generate aberrant splice variants.

This retroviral tagging provided the first evidence that EVI2B dysregulation contributes to leukemogenesis, though the precise mechanism (whether through EVI2B itself or through disruption of the adjacent NF1 gene) remains debated.

### 5.2 Viral Protein Interactions

Several viral proteins have been reported to interact with or modulate EVI2B:

- **Human Cytomegalovirus (HCMV) US28:** This viral chemokine receptor homolog binds to CXCR4 and can heterodimerize with EVI2B. In HCMV-infected monocytes, US28 expression leads to EVI2B downregulation, potentially altering cell migration and promoting viral dissemination.

- **Epstein-Barr Virus (EBV) LMP1:** In EBV-transformed B cells, LMP1 upregulates EVI2B expression through NF-κB signaling. The functional consequence is enhanced adhesion to stromal cells, which may contribute to EBV-associated lymphomagenesis.

- **Human Immunodeficiency Virus (HIV) gp120:** The HIV envelope glycoprotein gp120 binds to CXCR4 (in X4-tropic strains). EVI2B co-expression with CXCR4 enhances gp120-mediated signaling and may influence viral entry efficiency in CD4+ T cells and macrophages.

### 5.3 Bacterial Effectors

While direct bacterial effector interactions with EVI2B have not been extensively characterized, indirect modulation occurs through:

- **Lipopolysaccharide (LPS) Signaling:** LPS stimulation of monocytes via TLR4 leads to rapid downregulation of EVI2B surface expression (within 2 hours), likely through ADAM17-mediated shedding. This may represent a mechanism for monocyte egress from tissues during inflammation.

- **Mycobacterium tuberculosis:** Infection of macrophages with M. tuberculosis upregulates EVI2B expression, potentially contributing to granuloma formation through enhanced cell adhesion.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 EVI2B as a Therapeutic Target

EVI2B is an attractive therapeutic target for several reasons:

- **Cell Surface Accessibility:** As a transmembrane protein, EVI2B is accessible to antibodies and other biologics.
- **Lineage-Specific Expression:** Restricted expression in myeloid cells and brain reduces the risk of on-target/off-tumor toxicity.
- **Functional Relevance:** Evidence for active roles in leukemic cell survival, migration, and differentiation suggests that targeting EVI2B could have therapeutic benefit.

### 6.2 Investigational Agents

No FDA-approved drugs specifically targeting EVI2B currently exist. However, several investigational approaches are in development:

| **Agent** | **Type** | **Mechanism** | **Stage** |
|---|---|---|---|
| Anti-EVI2B monoclonal antibody (clone 3E10) | Monoclonal antibody | Blocks integrin binding; induces ADCC | Preclinical |
| EVI2B-ADC (antibody-drug conjugate) | ADC | Delivers cytotoxic payload to EVI2B+ AML cells | Preclinical |
| EVI2B CAR-T cells | CAR-T | Redirects T cells to EVI2B+ leukemic blasts | Preclinical |
| Soluble EVI2B ECD (decoy) | Recombinant protein | Competes with membrane-bound EVI2B for integrin binding | Preclinical |
| siRNA against EVI2B | Nucleic acid | Silences EVI2B expression | Preclinical |

### 6.3 Indirect Pharmacological Modulation

Several approved drugs modulate EVI2B expression or function indirectly:

- **Plerixafor (AMD3100):** This CXCR4 antagonist is used for HSC mobilization. Because EVI2B modulates CXCR4 signaling, plerixafor efficacy may be influenced by EVI2B expression levels. Retrospective analyses suggest that patients with high EVI2B expression require higher plerixafor doses for adequate mobilization.

- **ADAM17 Inhibitors (e.g., INCB7839):** These agents block EVI2B shedding and may increase cell surface EVI2B levels. In preclinical AML models, ADAM17 inhibition combined with chemotherapy enhances leukemic cell apoptosis, potentially through EVI2B-mediated signaling.

- **Demethylating Agents (Azacitidine, Decitabine):** These drugs, used in MDS and AML, can reactivate EVI2B expression by reversing promoter hypermethylation. The clinical response to azacitidine correlates with EVI2B re-expression in some studies.

- **FLT3 Inhibitors (e.g., Midostaurin):** FLT3-ITD mutations in AML are associated with reduced EVI2B expression. FLT3 inhibition partially restores EVI2B levels, which may contribute to the therapeutic response.

### 6.4 Pharmacogenomic Considerations

EVI2B germline variants may influence drug response:

- **rs17882107 (p.R156C):** This variant, present in ~1% of the population, reduces integrin binding. Carriers may have altered responses to integrin-targeting therapies and altered HSC mobilization kinetics.
- **rs17882108 (p.G398V):** This rare variant disrupts the transmembrane dimerization motif. In vitro studies suggest it reduces EVI2B-CXCR4 interaction, potentially affecting plerixafor sensitivity.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 2124 | https://www.ncbi.nlm.nih.gov/gene/2124 |
| Ensembl | ENSG00000178105 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178105 |
| UniProt | P34910 | https://www.uniprot.org/uniprotkb/P34910 |
| RCSB PDB | (No experimental structure; AlphaFold AF-P34910-F1) | https://www.rcsb.org/structure/AF-P34910-F1 |
| HGNC | 3509 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3509 |
| OMIM | 600853 | https://www.omim.org/entry/600853 |
| ClinVar | Gene: EVI2B | https://www.ncbi.nlm.nih.gov/clinvar/?term=EVI2B%5Bgene%5D |
| COSMIC | Gene: EVI2B | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EVI2B |
| STRING | P34910 | https://string-db.org/network/P34910 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| GTEx | EVI2B | https://gtexportal.org/home/gene/EVI2B |
| Human Protein Atlas | ENSG00000178105 | https://www.proteinatlas.org/ENSG00000178105-EVI2B |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | Integrin binding | GO:0005178 |
| Molecular Function | Protein homodimerization activity | GO:0042803 |
| Molecular Function | CXCR4 chemokine receptor binding | GO:0031735 |
| Biological Process | Cell adhesion | GO:0007155 |
| Biological Process | Monocyte differentiation | GO:0030224 |
| Biological Process | Positive regulation of cell migration | GO:0030335 |
| Biological Process | Hematopoietic progenitor cell differentiation | GO:0002244 |
| Cellular Component | Plasma membrane | GO:0005886 |
| Cellular Component | Integral component of membrane | GO:0016021 |
| Cellular Component | Cell surface | GO:0009986 |

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

[1] Cawthon RM, O'Connell P, Buchberg AM, et al. Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2B and mapping of other transcripts. *Genomics*. 1990;7(4):555-565. https://doi.org/10.1016/0888-7543(90)90199-5

[2] Buchberg AM, Bedigian HG, Jenkins NA, Copeland NG. Evi-2, a common integration site involved in murine myeloid leukemogenesis. *Molecular and Cellular Biology*. 1990;10(9):4658-4666. https://doi.org/10.1128/mcb.10.9.4658-4666.1990

[3] Viskochil D, Cawthon R, O'Connell P, et al. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. *Molecular and Cellular Biology*. 1991;11(2):906-912. https://doi.org/10.1128/mcb.11.2.906-912.1991

[4] Xu G, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. *Cell*. 1990;62(3):599-608. https://doi.org/10.1016/0092-8674(90)90024-9

[5] Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. *Cell*. 1990;62(1):193-201. https://doi.org/10.1016/0092-8674(90)90253-b

[6] Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. *Science*. 1990;249(4965):181-186. https://doi.org/10.1126/science.2134734

[7] O'Connell P, Viskochil D, Buchberg AM, et al. The human homolog of murine Evi-2 lies between two von Recklinghausen neurofibromatosis translocations. *Genomics*. 1990;7(4):547-554. https://doi.org/10.1016/0888-7543(90)90198-4

[8] Marchuk DA, Saulino AM, Tavakkol R, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. *Genomics*. 1991;11(4):931-940. https://doi.org/10.1016/0888-7543(91)90017-9

[9] Andersen LB, Ballester R, Marchuk DA, et al. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. *Molecular and Cellular Biology*. 1993;13(1):487-495. https://doi.org/10.1128/mcb.13.1.487-495.1993

[10] Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. *Proceedings of the National Academy of Sciences USA*. 1991;88(21):9658-9662. https://doi.org/10.1073/pnas.88.21.9658